Krakow, Poland – 5 June 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will exhibit at the upcoming 20th Annual Drug Discovery Summit, taking place on June 11-12, in Berlin, Germany. Throughout the whole event, Selvita’s team will be available at booth #8….
Selvita present at the EFMC-ACSMEDI MedChem Frontiers 2019 Conference
Krakow, Poland – 3 June 2019 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and development partner for the pharmaceutical and biotechnology industries, will present at the upcoming EFMC-ACSMEDI MedChem Frontiers 2019 Conference, taking place June 10-13, in Krakow. Throughout…
Selvita at the Annual BIO International Convention 2019
Krakow, Poland – 28 May 2019 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services will be present at the BIO International Convention, taking place on June 3-6 in Philadelphia, PA, USA. BIO International Convention…
Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update
– Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S. Food and Drug Administration (FDA) – – Dosing of first patient in Phase 1 study of SEL120 expected in the third quarter of 2019 – – Split of oncology therapeutics…
Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and…
Krakow, Poland – 16 May 2019 – Selvita today announced that abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for poster presentations at the 2019 American Society of Clinical Oncology (ASCO) annual meeting and 24th Annual European Hematology Association (EHA) Congress are now available online. The poster entitled “CLI24-001: First-in-human…
Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Krakow, Poland – 13 May 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that the company will present at the UBS Global Healthcare Conference, taking place on May 20-22 in New York. Chief Executive…